RecruitingPhase 4

Evaluation the Efficacy Between Botox Injection and Combination Pharmacotherapy in Patients With Detrusor Overactivity

Taiwan300 participantsStarted 2021-10-01

Plain-language summary

To investigates the effects of botulinum toxin type A bladder injection compared to combined pharmacotherapy with Mirabegron and Solifenacin.

Who can participate

Age range20 Years – 90 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients with detrusor overactivity which defined as a urodynamic observation characterized by involuntary detrusor contractions during the filling phase. Those who were refractory to monotherapy with either anti-muscarinics or β3-adrenoceptor agonists were enrolled for prospective study Exclusion Criteria: * Postvoid urine retention before treatment

What they're measuring

Short form of Urinary Distress Inventory (UDI-6)

Timeframe: Assess before treatment and 1 month, 3 months, 6 months and 1 year after treatment

Short form of Incontinence Impact Questionnaire (IIQ-7)

Timeframe: Assess before treatment and 1 month, 3 months, 6 months and 1 year after treatment

Overactive Bladder Symptom Score (OABSS)

Timeframe: Assess before treatment and 1 month, 3 months, 6 months and 1 year after treatment

Trial details

NCT IDNCT05968885

SponsorMackay Memorial Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-06-30

Contact for this trial

Hui-Hsuan Lau, MD

+886-2-25433535 huihsuan1220@gmail.com

View on ClinicalTrials.gov More Urinary Bladder, Overactive trials